VCYT (Veracyte) Asset Impairment Charge: $0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCYT Veracyte Inc VCYT
81 GF Score
Price $42.53
GF Value $38.89
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Veracyte Asset Impairment Charge?

Veracyte VCYT -4.75% 81 Asset Impairment Charge is $0.0 Mil as of Jun. 2026. GuruFocus rates VCYT with a GF Score™ of 81/100 and a GF Value™ of $38.89 (Fairly Valued). The stock has 4 warning signs investors should review.

Veracyte's Asset Impairment Charge for the three months ended in Jun. 2026 was $0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was $0.0 Mil.

Veracyte Asset Impairment Charge Related Terms

Veracyte Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Veracyte's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veracyte Asset Impairment Charge Chart

Veracyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.32 68.35 3.37 20.51

Veracyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VCYT
81GF Score
Veracyte Inc VCYT
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veracyte Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

What does a Asset Impairment Charge of $0.0 Mil mean?
Veracyte (VCYT) has a Asset Impairment Charge of $0.0 Mil as of Jun. 2026.
Is Veracyte's Asset Impairment Charge too high?
Veracyte's current Asset Impairment Charge is $0.0 Mil. Overall, Veracyte has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Veracyte's Asset Impairment Charge compare to GRAL and ADPT?
Veracyte's Asset Impairment Charge of $0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Medical Diagnostics & Research company?
A good Asset Impairment Charge depends on the Medical Diagnostics & Research industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Veracyte's current Asset Impairment Charge is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veracyte stock overvalued right now?
Based on GuruFocus' analysis, Veracyte (VCYT) is currently considered Fairly Valued. The stock's GF Value™ is $38.89, compared to a current price of $42.53 — trading 9.4% above its estimated fair value. The current Asset Impairment Charge is $0.0 Mil. Veracyte's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Veracyte (VCYT), the current Asset Impairment Charge is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $42.53 is trading 9.4% above its estimated GF Value™ of $38.89. GuruFocus considers Veracyte to be Fairly Valued.

Key valuation signals for VCYT:

  • Asset Impairment Charge: $0.0 Mil
  • GF Value™: $38.89 vs. price of $42.53 (9.4% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
81GF Score

Get the complete analysis for VCYT

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.53
Price
$38.89
GF Value